

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

13922

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5)

09/673490

INTERNATIONAL APPLICATION NO.

PCT/AU99/00288

INTERNATIONAL FILING DATE

16 April 1999 (16.04.99)

PRIORITY DATE CLAIMED

16 April 1998 (16.04.98) *

TITLE OF INVENTION

NOVEL OMEGA CONOTOXIN PEPTIDES

APPLICANT(S) FOR DO/EO/US

Roger Desmond Drinkwater, Richard James Lewis, Paul Francis Alewood and Katherine Justine Nielsen

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

**Courtesy copy international application
One (1) sheet of drawings**

*** Continuation of Priority Data
1 February 1999 (01.02.99)**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.5) 097673490	INTERNATIONAL APPLICATION NO. PCT/AU99/00288	ATTORNEY'S DOCKET NUMBER 13922
---	--	--

21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1,000.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$860.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$710.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$690.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$970.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	* 19 - 20 =	0	x \$18.00	\$0.00	
Independent claims	* 7 - 3 =	4	x \$80.00	\$320.00	
Multiple Dependent Claims (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS				=	\$1,420.00
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).				<input type="checkbox"/>	\$0.00
SUBTOTAL				=	\$1,420.00
Processing fee of \$130.00 for furnishing the English translation later than _____ <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				+	\$0.00
TOTAL NATIONAL FEE				=	\$1,420.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL FEES ENCLOSED				=	\$1,420.00
*claim calculation based on claims as amended by Preliminary Amendment being filed concurrently herewith				Amount to be: refunded	\$
				charged	\$

- ☒ A check in the amount of **\$1,420.00** to cover the above fees is enclosed.
- ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **19-1013/SSMP** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Leopold Presser
Registration No. 19, 827

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530
(516) 742-4343

SIGNATURE

Leopold Presser

NAME

19, 827

REGISTRATION NUMBER

October 16, 2000

DATE

09/673490

528 Rec'd PCT/PTO 16 OCT 2000

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Roger Desmond Drinkwater, et al.

Examiner: Unassigned

Serial No: Unassigned

Art Unit: Unassigned

Filed: Herewith

Docket: 13922

For: NOVEL OMEGA CONOTOXIN PEPTIDES

Dated: October 16, 2000

Assistant Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

In connection with the filing of the above-captioned application, kindly enter the following preliminary amendment.

AMENDMENTS

IN THE CLAIMS:

Please amend claims 3 and 8-13 as follows:

Claim 3, lines 1-2, delete "or claim 2";

Claim 8, lines 1-2, amend "anyone of the preceding claims" to read --claim 1--;


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number: **EL680252378US**

Date of Deposit: October 16, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Dated: October 16, 2000


Mishelle Mustafa

Claim 9, lines 1-2, amend "any one of the preceding claims" to read --claim 1--;

Claim 10, lines 2-3, amend "any one of claims 1 to 8" to read --claim 1--;

Claim 11, lines 3, amend "any one of claims 1 to 8" to read --claim 1--;

Claim 12, lines 1-2, amend "any one of claims 1 to 8" to read --claim 1--;


Claim 13, line 2, amend "any one of claims 1 to 8" to read --claim 1--.

REMARKS

As originally prepared, numerous claims did not comply with the multiple dependent claim style specified by U.S. law. The amendments submitted herewith have been made to delete all multiple dependencies. No new subject matter has been added by way of these amendments.

It is respectfully requested that the above amendments be entered before an action on the merits is issued.

Respectfully submitted,



Leopold Presser
Registration No. 19,827

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530

LP:am

NOVEL OMEGA CONOTOXIN PEPTIDES

This invention relates to novel peptides of the omega conotoxin (ω -conotoxin) class, and their use as pharmacological tools and in any indication where blockade of N-type calcium channels may be of benefit, for example in the reduction of neuronal damage following ischemia, production of analgesia, or enhancement of opiate analgesia, in the treatment of
5 schizophrenia, stimulant induced psychoses, hypertension, inflammation and diseases which cause bronchoconstriction, and in the inhibition of progression of neuropathic pain. The invention also relates to pharmaceutical compositions comprising these peptides and to nucleic acid probes useful in finding useful analogues of these peptides.

10 Predatory marine snails of the genus *Conus* (cone snails) are a diverse family of marine molluscs that immobilise their prey through the injection of venom. The venom is a complex mixture of peptides, known as conotoxins, which target a variety of different kinds of cellular receptor. The mixture of peptides that are found in the venom varies amongst species of cone snails as does the prey upon which the molluscs feed.

15

One particular family of peptides, known as the ω -conotoxins, isolated from such venoms have been found to target and block voltage sensitive calcium channels (VSCCs). These ω -conotoxins are reasonably small peptides (typically 24 to 32 amino acids) with six characteristic cysteine substitutions and a pattern of disulfide bonds. The pattern of the
20 disulfide links and the distribution of the cysteine residues mean that the peptide may notionally be considered to comprise four loops. The amino acids between cysteine residues 1 and 2, 2 and 3, 4 and 5, and 5 and 6 define loops, while cysteine residues 3 and 4 are adjacent.

25 Studies of different ω -conotoxins which have been either isolated from the complex peptide venoms of a variety of different species of *Conus*, or synthesised as chemical variants of known ω -conotoxins has provided an array of ω -conotoxins which display varying affinity and selectivity for various sub-types of neuronal calcium channels. Such is the affinity of some of these peptides for VSCCs that a number of the ω -conotoxins have become important
30 research tools for defining different sub-types of neuronal voltage sensitive calcium channel.

- 2 -

In mammalian systems, ω -conotoxins such as GVIA have a high level of selectivity for N-type calcium channels whilst other ω -conotoxins such as MVIIC have a low affinity for the N-type channel but bind strongly to P/Q-type channels. Labelled forms of these ligands (for example ¹²⁵Iodinated MVIIA) are routinely used in pharmacological assays relating to VSCCs.

5

Whilst the available conotoxins are useful in defining a number of calcium channel sub-types new ligands displaying different binding profiles and affinities may be useful in further defining channel sub-types.

10 In addition to their use as research tools, ω -conotoxins which target N-type calcium channels have been proposed for use in the treatment of a variety of conditions including ischaemia induced brain injury, acute psychotic episodes which may be drug induced or result from a psychiatric disorder, diseases which cause bronchoconstriction, hypertension, inflammation and chronic pain. They may also be used in the treatment of schizophrenia, in the production
15 of analgesia and the enhancement of opiate induced analgesia. The compounds of the invention may be useful in any indication where blockade of N-type calcium channels may be of benefit. One particular ω -conotoxin, known as MVIIA or, in its synthetic form, SNX-111, is in clinical trials for some of these applications.

20 Despite these advances in the use of ω -conotoxins the presently available compounds are not ideal therapeutics. For example, SNX-111 has been reported to cause hypotension as a result of action at peripheral channels. Another of the ω -conotoxins, GVIA, is a potent antagonist of N-type calcium channels but binds to such channels in an irreversible manner, and accordingly is unsuitable as a therapeutic. Many other of the known ω -conotoxins do not
25 have an adequate level of selectivity for the N-type channel to be deemed suitable therapeutic candidates; blockade of P/Q-type channels may lead to death.

Accordingly there exists a need for new therapeutic agents which have a selectivity for N-type calcium channels over P/Q type channels, and which may be useful in the treatment of
30 conditions related to N-type calcium channels.

- 3 -

In a first aspect of the present invention there is provided an isolated, synthetic or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

5 SGTVGR [SEQ ID NO:1]

or such a sequence which has undergone one or more amino acid substitutions, or side chain modifications.

10 Preferably the fourth loop consists of the above sequence, or such a sequence which has undergone one or more conservative amino acid substitutions or side chain modifications.

Preferably each of the first, second and third loops of the ω -conotoxin peptide correspond to the loop of a naturally occurring ω -conotoxin peptide, or such a sequence of amino acids
15 which has undergone one or more amino acid substitutions, additions or deletions.

Substitutions encompass amino acid alterations in which an amino acid is replaced with a different naturally-occurring or a non-conventional amino acid residue. Such substitutions may be classified as "conservative", in which case an amino acid residue contained in a
20 polypeptide is replaced with another naturally-occurring amino acid of similar character, for example Gly \rightarrow Ala, Val \rightarrow Ile \rightarrow Leu, Asp \rightarrow Glu, Lys \rightarrow Arg, Asn \rightarrow Gln or Phe \rightarrow Trp \rightarrow Tyr. It is to be understood that some non-conventional amino acids may also be suitable replacements for the naturally occurring amino acids. For example ornithine, homoarginine and dimethyllysine are related to His, Arg and Lys.

25 Substitutions encompassed by the present invention may also be "non-conservative", in which an amino acid residue which is present in a polypeptide is substituted with an amino acid having different properties, such as naturally-occurring amino acid from a different group (eg. substituting a charged or hydrophobic amino acid with alanine), or alternatively, in which a
30 naturally-occurring amino acid is substituted with a non-conventional amino acid.

- 4 -

Amino acid substitutions are typically of single residues, but may be of multiple residues, either clustered or dispersed.

Preferably, amino acid substitutions are conservative.

5

Additions encompass the addition of one or more naturally occurring or non-conventional amino acid residues. Deletion encompasses the deletion of one or more amino acid residues.

As stated above the present invention includes peptides in which one or more of the amino acids
10 has undergone sidechain modifications. Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS);
15 acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

20

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid
25 or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH. Any modification of cysteine
30 residues must not affect the ability of the peptide to form the necessary disulphide bonds. It is also possible to replace the sulphydryl group of cysteine with selenium equivalents such that the

- 5 -

peptide forms a diselenium bond in place of one or more of the disulphide bonds.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.

5 Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

10

Proline residue may be modified by, for example, hydroxylation in the 4-position.

Some amino acid residues, for example methionine, may under some conditions be prone to oxidation. In some cases the oxidised residue may retain biological activity similar to that of the
15 parent peptide and accordingly the oxidised form of the peptides are considered within the scope of the present invention, for example CVID where the methionine residue is oxidised. However, oxidation of an amino acid residue may in some cases lead to a decrease in activity or selectivity. Accordingly, where oxidisable residues are present they may be replaced with another amino acid. Replacement may be with an amino acid having similar properties, for example charge and
20 size, or may be with an amino acid having different properties. For example, in the case of CVID the methionine residue at position 12 may be replaced with, for example, norleucine, O-methyl serine, O-methyl homoserine or alanine.

A list of some amino acids having modified side chains and other unnatural amino acids are
25 shown in Table 1.

- 6 -

TABLE 1

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbonyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine		Chexa L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva

03673496-14400

- 7 -

09673430 44400

	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgab
	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpn
5	D- α -methylassparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylasspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
10	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methyllleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
15	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
20	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylassparagine	Dnmasn	N-cycloundecylglycine	Ncund
25	D-N-methylasspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
30	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methyllleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp

	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
5	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
10	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
15	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
20	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
25	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
	N-(N-(2,2-diphenylethyl) carbamylmethyl)glycine	Nnbhm	N-(N-(3,3-diphenylpropyl) carbamylmethyl)glycine	Nnbhe
30	1-carboxy-1-(2,2-diphenyl-ethylamino)cyclopropane	Nmbc	L-O-methyl serine	Omser
			L-O-methyl homoserine	Omhser

- 9 -

These types of modifications may be important to stabilise the peptide if administered to an individual or for use as a diagnostic reagent. Other modifications may be made to the peptide in order to stabilise it or enhance other of its properties, for example membrane penetration or solubility. Such modifications include modifying the side chain of one or more amino acids to attach other types of group, for example a lipophilic group. Such attachment may be made through a linking group designed to space the other group or groups away from the peptide so as not to interfere with the activity of the peptide. Those skilled in the art will readily be able to determine how to modify the peptides of the invention. All such modified forms of the peptide are considered within the scope of the present invention.

Other derivatives contemplated by the present invention include a range of glycosylation variants from a completely unglycosylated molecule to a modified glycosylated molecule. Altered glycosylation patterns may result from expression of recombinant molecules in different host cells.

The ω -conotoxins of the present invention are typically amidated at the C-terminal however compounds with a free carboxyl terminus or other modifications at the C-terminal are considered to be within the scope of the present invention. Preferably the peptides are amidated or have a free carboxyl.

Preferably the peptides will retain the Cys residues and characteristic disulphide bonding pattern. Peptides may include additional Cys residues provided they are protected during formation of the disulphide bonds.

Preferably the peptide has a second loop which comprises a sequence selected from:

SKLMYD	[SEQ ID NO: 2],
SRLMYD	[SEQ ID NO: 3],

- 10 -

DRLMYD [SEQ ID NO: 4],
 DKLMYD [SEQ ID NO: 33],
 SKLAYD [SEQ ID NO: 34],
 SKLNleYD [SEQ ID NO: 35],
 5 SRLNleYD [SEQ ID NO: 36],
 SKLOhnhserYD [SEQ ID NO: 37],
 SKLOmserYD [SEQ ID NO: 38],

or such a sequence which has undergone one or more conservative amino acid substitution
 10 or side chain modifications.

In a particularly preferred embodiment the ω -conotoxin peptide has the following sequence:

CVID (1) CKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 5]
 15 1 2 3 4

The four loops are shown underlined. This peptide was isolated from *Conus catus* and has
 been designated herein as CVID. The peptide has been shown to have a high potency and
 a high selectivity for N-type calcium channel over P/Q-type calcium channel in receptor
 20 binding assays. Two modified forms of CVID have also been shown to have a high potency
 and high selectivity for N-type calcium channel. These are designated R¹⁰-CVID and D⁹R¹⁰-
 CVID as follows:

R¹⁰-CVID (2) CKSKGAKCSRLMYDCCSGSCSGTVGRC [SEQ ID NO: 6]
 25
 D⁹R¹⁰-CVID (3) CKSKGAKCDRLMYDCCSGSCSGTVGRC [SEQ ID NO: 7]

The peptides according to the present invention may be naturally occurring conotoxin
 peptides, such as CVID, or may be derivatives of such naturally occurring peptides. The
 30 derivatives of the naturally occurring conotoxin peptides may differ from their naturally

occurring counterparts by one or more amino acid substitutions, deletions or additions as described above.

In modification to form derivatives of naturally occurring peptides it is useful to compare
5 the amino acid sequences of active naturally occurring peptides to determine which, if any, of the residues are conserved between active species. Substitution of these conserved residues, while not prohibited, is less favoured than substitutions of non-conserved residues.

Derivatives where Ala replaces one or more residues can be used to identify the
10 pharmacophore. Preferably only one or two amino acids is replaced with Ala at a time. Additional new peptides can be made where charged, polar or hydrophobic residues, respectively, are replaced to assist defining more precisely the type of interactions involved in the binding of this pharmacological class of peptide to its receptor. Non-conservative replacements, where charge is reversed, or polar residues replace hydrophobic residues, can
15 further identify residues involved in binding. All of these peptides have potential to show improved potency, or greater selectivity. Non-native amino acid changes could also be included to improve potency, selectivity and/or stability.

Exposed residues are most likely to be involved in receptor binding and can be
20 systematically replaced. Particular emphasis is placed on changing residues involved in binding and residues just on the periphery of the pharmacophore, using longer side chain forms or non-conserved changes to pick up additional binding interactions for improved potency and/or selectivity.

25 Three-dimensional ^1H NMR studies, of the type known to those skilled in the art (Nielsen *et al.* 1996 and 1999) and further described in Example 5, indicate that CVID adopts a similar fold to known ω -conotoxins such as MVIIA. However, unlike those ω -conotoxins, loop 4 of CVID is found in a different orientation to that of the known ω -conotoxins and CVID also has two hydrogen bonds which hold loops 2 and 4 together; factors that may
30 contribute to the ability of CVID to discriminate among VSCCs.

- 12 -

In view of this novel confirmation of loop 4 and the stabilisation between loops 2 and 4 of CVID, one preferred group of derivatives are those which maintain an orientation of loop 4 similar to that seen in CVID. A further preferred group of derivatives are those ω -conotoxins which have an interaction or interactions between loops 2 and 4 which stabilise the confirmation of loops 2 and 4. Those skilled in the art may readily determine the three-dimensional structure of particular peptides, the orientation of loop 4 and interactions between the loops.

Another preferred group of derivatives are those which maintain or only have conservative substitutions at residues 10, 11, 22 and 23 of CVID.

In another embodiment of the present invention there is provided a chimeric ω -conotoxin peptide in which one or more of loops 1 to 3 of conotoxin CVID have been substituted with the corresponding loop of a different ω -conotoxin.

15

A preferred group of derivatives of CVID are those ω -conotoxin peptides which maintain certain residues of CVID. These derivatives are represented in the following sequence

$$\text{CxxxGxxCxKLxYxCCxSCSGxVGRC}$$

where each x may be any other amino acid and up to one x may be a deletion. Preferred selections for x would be the corresponding natural amino acids from ω -cono-peptides with N-type BSCC selectivity and conservative substitutions or alanine substitutions of those amino acids, all of which may also have modified side chains. For example, methionine may be replaced with O-methyl serine or O-methyl homoserine.

25 Some known conotoxins are as follows:

MVIIA (SNX-III)

CKGKGAKCSRLMYDCCTGSCRSGKC [SEQ ID NO: 8]

MVIIC

CKGKGAPCRKTMVDCCSGSCGRRGKC [SEQ ID NO: 9]

- 13 -

GVIA

CKSOGSSCSOTSYNCCRSCNOYTKRCY [SEQ ID NO: 10]

In the sequence for GVIA the "O" refers to 4-hydroxy proline (Hyp). This amino acid residue results from post translational modification of the encoded peptide and is not directly
5 encoded by the nucleotide sequence.

Chimeric ω -conotoxins contemplated by the present invention include DADD, DAGD and GGGD. Where a D, A or a G represent loops selected from CVID, MVIIA or GVIA respectively. Accordingly DADD corresponds to loops 1, 3 and 4 being selected from
10 CVID and loop 2 being selected from MVIIA, this chimeric ω -conotoxin is the same as R¹⁰-CVID.

A number of other ω -conotoxin peptides according to the invention were found to be encoded by mRNA isolated from *Conus catus* according to the general procedure described
15 in Example 3. These encoded peptides were synthesised by standard procedures and may be considered as derivatives of CVID, the sequences are as follows:

- | | | |
|--------|-----------------------------|-----------------|
| (4) | CRSKGAKCSKLMYDCCSGSCSGTVGRC | [SEQ ID NO: 14] |
| (5) | CKSKGARCSKLMYDCCSGSCSGTVGRC | [SEQ ID NO: 15] |
| 20 (6) | CKSKGAQCSKLMYDCCSGSCSGTVGRC | [SEQ ID NO: 16] |
| (7) | CKSKGAKCSKLMYDCCSGSCSGAVGRC | [SEQ ID NO: 17] |

Examples of other derivatives of CVID include the following sequences:

- | | | |
|---------|--------------------------------|-----------------|
| 25 (8) | CKSKGAKCDKLMYDCCSGSCSGTVGRC | [SEQ ID NO: 18] |
| (9) | CKYKGAKCSRLMYDCCSGSCSGTVGRC | [SEQ ID NO: 19] |
| (10) | CKSKGAKCSKLAYDCCSGSCSGTVGRC | [SEQ ID NO: 20] |
| (11) | CKSKGAKCSKLMYDCCTGSCSGTVGRC | [SEQ ID NO: 21] |
| (12) | CKSKDalAKCSKLMYDCCSGSCSGTVGRC | [SEQ ID NO: 22] |
| 30 (13) | CKSKGAKCSKLMYDCCSGSCSGTVGRCY | [SEQ ID NO: 23] |
| (14) | CKSKGAKCSKLMYDCCSGSCSGTVGRC-OH | [SEQ ID NO: 24] |

- 14 -

- (15) YCKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 25]
 (16) AcCKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 26]
 (17) CKSKGAKCSKLNleYDCCSGSCSGTVGRC [SEQ ID NO: 27]
 (18) CKSKGAKCSRLNleYDCCSGSCSGTVGRC [SEQ ID NO: 28]
 5 (19) CKYKGAKCSRLNleYDCCSGSCSGTVGRC [SEQ ID NO: 29]
 (20) CKSKGAKCSKLOmhserYDCCSGSCSGTVGRC [SEQ ID NO: 30]
 (21) CKSKGAKCSKLOmserYDCCSGSCSGTVGRC [SEQ ID NO: 31]
 (22) CKSKGAKCSKLM(O)YDCCSGSCSGTVGRC [SEQ ID NO: 32]

10 Compounds (13) and (15) (SEQ ID NOS: 23 and 25) have an additional amino acid at the C-terminal and N-terminal respectively.

Compound (14) (SEQ ID NO: 24) has a free carboxyl at the C-terminal.

15 Compound (16) (SEQ ID NO: 26) is acylated at the N-terminal.

Compound (22) (SEQ ID NO: 32) has the methionine residue oxidised to its sulfoxide.

Compounds (10), (17), (2), and (21) (SEQ ID NOS: 20, 27, 30 and 32, respectively) represent
 20 methionine replacements.

A preferred group of ω -conotoxin peptides are CVID, compounds (4), (5), (10), (17), (18), (20), and (21). A particularly preferred ω -conotoxin peptides is CVID.

25 In the accompanying sequence listing the amino acids Xaa are as shown in Table 2.

Table 2

SEQ ID NO:	Xaa
SEQ ID NO: 22	Dal

- 15 -

SEQ ID NO:	Xaa
SEQ ID NO: 27	Nle
SEQ ID NO: 28	Nle
SEQ ID NO: 29	Nle
SEQ ID NO: 30	Omhser
SEQ ID NO: 31	Omser
SEQ ID NO: 35	Nle
SEQ ID NO: 36	Nle
SEQ ID NO: 37	Omhser
SEQ ID NO: 38	Omser

10

The peptides according to the present invention preferably have a selectivity for N-type calcium channel over P/Q type calcium channel. The terms "selective" and selectivity" as used herein mean that the binding activity of the peptide at the N-type calcium channel is greater than the binding activity at the P/Q-type calcium channel. Those skilled in the art would be able to readily determine the selectivity of the peptides for these calcium channels using standard techniques.

Iodinated GVIA and MVIIC are high affinity ligands for the N-type and P/Q type calcium channel receptors respectively and are routinely used in receptor binding assays (Kristipati *et al.*, 1994; Nadasdi *et al.*, 1995). Such assays may be used to test the calcium channel binding activity of the peptides of the present invention. Functional assays such as those described by Lew *et al.* (1997) may also be useful in determining activity at N-type calcium channels. The peptides according to the present invention may also be used in such assays.

The ω -conotoxins of the present invention may be used, typically in labelled form such as radioiodinated CVID, to run assays and/or screens to identify compounds which interact with N-type calcium channels and/or particular sub-types of such channels. Those skilled

- 16 -

in the art could readily establish such assays and/or screens. A variety of labelled versions of the compounds of the present invention may be readily prepared by standard methods and assessed for retention of their ability to bind to N-type calcium channels in standard assays. Labelled versions of the compounds which do retain the ability to bind to N-type
5 calcium channels or binding portions of such channels could then be used in assays and/or screens. Accordingly, the present invention extends to the use of the peptides of the invention in screens to identify compounds with activity at N-type VSCCs.

The ω -conotoxins of the present invention may be prepared using standard peptide
10 synthetic methods followed by oxidative disulfide bond formation. For example, the linear peptides may be synthesised by solid phase methodology using BOC chemistry, as described by Schnoltzer *et al* (1992). Following deprotection and cleavage from the solid support the reduced peptides are purified using preparative chromatography. The purified reduced peptides are oxidised in buffered systems, for example as described in example 2.
15 The oxidised peptides were purified using preparative chromatography.

References describing the synthesis of conotoxins include Sato *et al*, Lew *et al* and WO 91/07980.

20 The ω -conotoxins may also be prepared using recombinant DNA technology. A nucleotide sequence encoding the desired peptide sequence may be inserted into a suitable vector and protein expressed in an appropriate expression system. In some instances, further chemical modification of the expressed peptide may be appropriate, for example C-terminal amidation. Under some circumstances it may be desirable to undertake
25 oxidative bond formation of the expressed peptide as a chemical step following peptide expression. This may be preceded by a reductive step to provide the unfolded peptide. Those skilled in the art may readily determine appropriate conditions for the reduction and oxidation of the peptide.

30 Naturally occurring CVID was isolated from *Conus catus* by assay guided fractionation of

- 17 -

the venom followed by sequencing of the purified peptide.

The invention further provides an isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to sequence encoding a ω -conotoxin peptide as
5 described above.

In a further aspect of the present invention there is provided a nucleic acid probe comprising a sequence of nucleotides encoding or complementary to a sequence encoding ω -conotoxin peptides having a fourth loop of CVID, said probe encoding or
10 complementary to all or part of loop 4 of the ω -conotoxin CVID, or such a sequence which has undergone one or more amino acid substitution or side chain modifications.

In a particularly preferred embodiment the nucleic acid probe comprises a sequence of nucleotides encoding or complementary to a sequence encoding the sequence shown in
15 SEQ ID NO: 1.

As used herein a reference to a "probe" includes reference to a primer used in amplification or a probe for use in direct hybridization.

20 Still another aspect of the present invention is directed to antibodies to the ω -conotoxin peptides according to the invention. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to the peptides or may be specifically raised to the peptides using standard techniques. In the case of the latter, the peptides may first need to be associated with a carrier molecule. The antibodies of the present invention
25 are particularly useful as therapeutic or diagnostic agents.

In this regard, specific antibodies can be used to screen for the peptides according to the invention. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA. Knowledge of peptide levels may be important for monitoring
30 certain therapeutic protocols.

The nucleic acid molecules of the present invention may be DNA or RNA. When the nucleic acid molecule is in DNA form, it may be genomic DNA or cDNA. RNA forms of the nucleic acid molecules of the present invention are generally mRNA.

- 5 Although the nucleic acid molecules of the present invention are generally in isolated form, they may be integrated into or ligated to or otherwise fused or associated with other genetic molecules such as vector molecules and in particular expression vector molecules. Vectors and expression vectors are generally capable of replication and, if applicable, expression in one or both of a prokaryotic cell or a eukaryotic cell. Preferably, prokaryotic cells include *E.*
10 *coli*, *Bacillus sp* and *Pseudomonas sp*. Preferred eukaryotic cells include yeast, fungal, mammalian and insect cells.

Accordingly, another aspect of the present invention contemplates a genetic construct comprising a vector portion and a gene capable of encoding a peptide according to the
15 invention.

Preferably, the gene portion of the genetic construct is operably linked to a promoter on the vector such that said promoter is capable of directing expression of the gene portion in an appropriate cell.

20

The present invention extends to such genetic constructs and to prokaryotic or eukaryotic cells comprising same.

In view of their high potency and selectivity towards N-type calcium channel over P/Q
25 type the ω -conotoxin peptides of the present invention may be useful in any indications where blockade of N-type calcium channels may be of benefit. Such indications include the reduction of neuronal damage following ischemia, production of analgesia, enhancement of opiate analgesia, treatment of schizophrenia, stimulant psychoses, hypertension, inflammation and diseases which cause bronchoconstriction, and inhibition
30 of progression of neuropathic pain. Analgesia means the relief of pain generally and includes relief of acute, persistent or neuropathic pain. Preferred indications where the

- 19 -

peptides may be useful include production of analgesia, enhancement of opiate analgesia, and inhibition of progression of neuropathic pain.

Assays useful for assessing compounds with activity at N-type calcium channels, such as the ω -conotoxins of the present invention, may be *in vitro* or *in vivo* assays and are known to those skilled in the art. Examples of assays include those described or referenced in WO91/07980, WO93/13128, US5,824,645, WO97/04797, Drugs of the Future (1994 and 1998), Drug Data Report (1993), or Heading (1999).

Particular assays which may be of use include; *in vitro* binding assays; nociceptive tests such as the formalin test and the hot-plate tests (Molmberg and Yaksh, 1995), the tail flick and mechanical paw pressure tests (Omote *et al.*, 1996), or models of neuropathic pain (White and Cousins, 1998); neuroprotective tests such as the rat 4-vessel occlusion model or *in vitro* cell survival assays; other assays looking at effects on neurotransmitter release, for example Substance P (Ray *et al.*, 1991; Cabot *et al.*, 1998).

The ω -conotoxins of the present invention have shown useful activity in some of these assays

Accordingly in a further aspect of the present invention there is provided a composition comprising: an isolated, synthetic or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

SGTVGR [SEQ ID NO: 1]

25

or such a sequence which has undergone one or more conservative amino acid substitutions, and

a pharmaceutically acceptable carrier or diluent.

30

There is also provided the use of an isolated, synthetic or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

or such a sequence which has undergone one or more conservative amino acid
10 substitutions or side chain modifications in the manufacture of a medicament for the
reduction of neuronal damage following ischemia, production of analgesia, enhancement
of opiate analgesia, treatment of schizophrenia or the treatment of stimulant psychoses,
hypertension, inflammation, diseases which cause bronchoconstriction, or for inhibition of
progression of neuropathic pain.

The invention further provides a method for reducing neuronal damage following ischemia, for the production of analgesia, for enhancement of opiate analgesia, for the treatment of schizophrenia, stimulant psychoses, hypertension, inflammation, diseases which cause bronchoconstriction, or for inhibition of progression of neuropathic pain, including the step of administering to a mammal an effective amount of an isolated or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

25

Preferably the mammal is in need of such treatment, although the peptide may be
30 administered in a prophylactic sense.

As will be readily appreciated by those skilled in the art, the route of administration and the nature of the pharmaceutically acceptable carrier will depend on the nature of the condition and the mammal to be treated. It is believed that the choice of a particular carrier or delivery system, and route of administration could be readily determined by a person skilled in the art. In the preparation of any formulation containing the peptide actives care should be taken to ensure that the activity of the peptide is not destroyed in the process and that the peptide is able to reach its site of action without being destroyed. In some circumstances it may be necessary to protect the peptide by means known in the art, such as, for example, micro encapsulation. Similarly the route of administration chosen should be such that the peptide reaches its site of action.

The pharmaceutical forms suitable for injectable use include sterile injectable solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions. They should be stable under the conditions of manufacture and storage and may be preserved against oxidation and the contaminating action of microorganisms such as bacteria or fungi .

Those skilled in the art may readily determine appropriate formulations for the peptides or modified peptides of the present invention using conventional approaches. Identification of preferred pH ranges and suitable excipients, for example antioxidants, is routine in the art (see for example Cleland *et al*, 1993). Buffer systems are routinely used to provide pH values of a desired range and include carboxylic acid buffers for example acetate, citrate, lactate and succinate. A variety of antioxidants are available for such formulations including phenolic compounds such as BHT or vitamin E, reducing agents such as methionine or sulphite, and metal chelators such as EDTA.

The solvent or dispersion medium for the injectable solution or dispersion may contain any of the conventional solvent or carrier systems for peptide actives, and may contain, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the

required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about where necessary by the inclusion of various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include agents to
5 adjust osmolality, for example, sugars or sodium chloride. Preferably, the formulation for injection will be isotonic with blood. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. Pharmaceutical forms suitable for injectable use may be delivered by any appropriate route including intravenous, intramuscular, intracerebral,
10 intrathecal, epidural injection or infusion.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients such as these enumerated above, as required, followed by filtered sterilization. Generally, dispersions are
15 prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred methods of preparation are vacuum drying or freeze-drying a of a previously sterile-filtered solution of the active ingredient plus any additional desired
20 ingredients.

When the active ingredients are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in
25 hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations preferably contain at least 1% by weight of active compound.
30 The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of

- 23 -

active compound in such therapeutically useful compositions in such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and the like may also contain the components as listed hereafter: A binder such as gum, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound(s) may be incorporated into sustained-release preparations and formulations.

The present invention also extends to any other forms suitable for administration, for example topical application such as creams, lotions and gels, or compositions suitable for inhalation or intranasal delivery, for example solutions or dry powders.

Parenteral dosage forms are preferred, including those suitable for intravenous, intrathecal, intracerebral or epidural delivery.

25

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated.

Supplementary active ingredients can also be incorporated into the compositions.

- 24 -

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the
5 desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased
10 condition in which bodily health is impaired as herein disclosed in detail.

The principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active compound in amounts ranging
15 from 0.25 μ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.25 μ g to about 200 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

20 In order to facilitate an understanding of the invention reference will be made to the examples and figure which illustrate some preferred embodiments of the invention. However it is to be understood the generality of the preceding description is not to be superseded by the particularity of the following description.

25 Referring to the figure:

Figure 1 is an example of a nucleic acid sequence encoding CVID. The amino acid sequence including the leader sequence and terminal glycine is also shown. The nucleic acid sequence and amino acid sequence are also shown as SEQ ID NO: 12 and SEQ ID NO: 13
30 respectively, while the nucleic acid encoding the fourth loop is shown in SEQ ID NO: 11. The primary nucleotide sequence is 382bp in length and comprises the leader sequence

- 25 -

- (amino acid residues 1 to 45), the mature peptide (amino acid residues 46 to 73 and boxed), the 3' untranslated region (depicted by lower case lettering immediately following the region of the mature peptide), and a small portion of the 5' untranslated region that was incorporated into the CSRD-301A primer (depicted in bold italicised lower case lettering at the start of the sequence). The start and stop codons delineating the peptide coding region are underlined. The putative amino acid sequences for the leader and mature peptides have been translated from the primary nucleotide sequence and are shown in single letter abbreviation below the nucleotide sequence. The numbering above the nucleotide sequence relates to the position of the amino acid residues taken from the start codon. The position of the CSRD-301A PCR primer within the CVID sequence is highlighted in bold and italicised: the ANCHOR primer would be positioned immediately 3' to the poly-A tail (at 382+bp). An arrow at the arginine residue at position 45 indicates the most probable site for enzymatic cleavage of the leader peptide from the mature peptide.
- The terminal glycine of the predicted expressed protein is removed by some form of post translational modification to leave an amidated C-terminal cystine in the protein isolated from snails.

EXAMPLES

20

Example 1

Assay guided fractionation of the venom of *Conus catus* was performed as follows:

- The omega conotoxin CVID (1) was isolated originally from the crude venom extracted from the venom ducts of *Conus catus* collected from the Great Barrier Reef, Australia. Using gradient reverse phase HPLC the crude venom was separated into a number of fractions and these fractions then assayed in a ^{125}I GVIA binding assay (see Example 4). Fractions active in the binding assay were further purified by assay-guided reverse phase HPLC and the primary structure obtained unambiguously by Edman sequencing. The fraction corresponding to CVID had a retention time of around 25-27 minutes.

- 26 -

The reverse phase HPLC was conducted on a Waters 600 HPLC system on preparative and analytical Vydac C18 columns. Samples were typically run using a 1% gradient (100% A, 5 min; 100% A to 60% B, 60 min) at 1 ml/min and monitored at 214 nm. Additional fractionation was at times achieved using size-exclusion HPLC. Fractions for assay were collected either at 1 minute intervals or to correspond to peaks detected with a u.v. detector. The buffer system used for all analysis was A=0.1%TFA in H₂O and B=0.09%TFA, 10%H₂O, 90%CH₃CN.

10 Example 2

The synthesis of peptides was performed according to the following procedures.

Materials and Methods

15

Materials

Synthesis of C-terminal amidated peptides was conducted on *p*-MBHA resin, obtained from Peninsula Laboratories and Peptide Institute, substitution values ranged from 0.66 to 0.93meq/g. C-terminal acids were synthesised on Boc protected PAM resins obtained from Applied Biosystems. Boc protected amino acids were obtained from Peptide Institute, BA Chem, Nova Biochem, Fluka, Biosearch and Auspep. The side-chain protection chosen for the boc amino acids was Arg(Tos), Asn(Xan), Asp(OcHex), His(DNP), Lys(ClZ), Thr(Bzl), Tyr(BrZ), Glu(OcHex), Ser(Bzl), HyP(Bzl), Trp(CHO), Cys(*p*-MeBzl), Gln(Xan). All other Boc amino acids used were side-chain unprotected. DMF, DCM, DIEA, TFA, dicyclohexylcarbodiimide and hydroxybenzotriazole were all peptide synthesis grade from Auspep (Melbourne, Australia). Acetonitrile and methanol (Hipersolve-Far UV grade) were from BDH (Poole, UK). Water was obtained from a tandem Millipore Milli-RO - Milli-Q system. *p*-cresol and *p*-thiocresol were from Fluka (Germany). HF was supplied by BOC Gases (Brisbane, Australia). Ammonium acetate (AR) and ammonium sulphate (AR) were from AJAX Chemicals (Australia). Guanidine. HCl (99%+) and reduced and oxidised

- 27 -

Glutathione were from Sigma Aldrich (USA).

Methods

5

Synthesis

Automatic peptide synthesis was conducted on an Applied Biosystems 430A synthesiser, using symmetric anhydride or active ester chemistries to couple Boc-protected amino acids to the resin. Manual stepwise synthesis was conducted using BOC chemistry methodology, where 2mmol of each amino acid is activated using 4ml of 0.5M HBTU in DMF and 470 μ l DIEA, and *in-situ* coupling takes on average 10min to obtain >99% coupling by quantitative ninhydrin² analysis. Both methods involved starting from *p*-MeBHA or PAM resin (0.5mmol scale). Where -OCH₂-PAM resin was used the first amino acid was on the resin. Removal of the Boc protecting group prior to coupling was accomplished by vortexing or shaking in 100%TFA. DMF was used for flow washes and as the coupling solvent. Each residue (2mmol) was routinely double coupled on the synthesiser and in the manual synthesis when ninhydrin values indicated less than 99% coupling. If coupling remained less than 99%, the remaining amino groups were acetylated using acetic anhydride in DMF (87 μ l/ml).

20

Deprotection and Cleavage

For peptides containing histidine-DNP, the fully protected peptide was first subjected to thiolysis (20% β -mercaptoethanol, 10% DIEA in DMF, 2 x 30min), to remove the side-chain protection. The N- α -Boc group was then removed (TFA, 2 x 1min), and for peptides containing tryptophan-CHO, deformylation was performed using a solution of ethanolamine (1.5g) in 25ml 5% water in DMF (2 x 30min). The peptide was washed with DCM and dried under nitrogen. Cleavage from the resin and simultaneous deprotection of side-chains was carried out in liquefied HF in the presence of the scavengers *p*-cresol and *p*-thiocresol (18:1:1 by volume) at -5 - 5°C for 1.5hr. HF was removed under vacuum, the peptide was precipitated with cold ether, collected by filtration on a sintered funnel and washed with cold

ether to remove scavenger adducts. The peptide was dissolved in either 50% AcOH or 45% aqueous acetonitrile, diluted with water and lyophilised.

Folding and Oxidation

5

Purified reduced peptides were oxidised at a concentration of 0.02 to 0.05mM in either aqueous 0.33M NH₄OAc / 0.5M GnHCl, or aqueous 2M (NH₄)₂SO₄ / 0.1M NH₄OAc with pH adjusted to 7.5 - 8.0 using 0.01M NH₄OH. The solution was stirred for 3 to 5 days at 4°C, in the presence of reduced and oxidised glutathione (molar ratio of peptide:GSH:GSSG was 1:100:10). The reaction mixtures were sampled periodically and analysed by RP-HPLC and eluant fractions were collected for electrospray mass spectrometric analysis. When LC and MS confirmed that oxidation was complete, the oxidation was terminated by lowering the pH to 2-3 with TFA.

15 Chromatographic Analysis and Purification

A Waters 600 HPLC system equipped with an auto-injector was used for all RP-HPLC. Analytical RP-HPLC was conducted on a Waters Delta pak C18, 300A (0.39 x 30cm) column or a Vydac C18, 5μ (0.46 x 25cm) column. Samples were run using a 1% gradient (100%A, 5min; 100%A to 60%B, 60min), at 1ml/min and monitored at 214nm. The buffer system used for all analysis was A=0.1%TFA in H₂O and B=0.09%TFA, 10%H₂O, 90%CH₃CN.

A Vydac C18, 5μ (1.0 x 25cm) column was used for semipreparative RP-HPLC and a Vydac C18, 10μ (2.2 x 25cm) column was used for preparative RP-HPLC.

The crude reduced peptides were purified by preparative chromatography, using a 1% gradient (100%A to 80%B, 80min) with a flow rate of 8ml/min and u.v detection at 230nm. Fractions were collected and analysed by electrospray mass spectrometry. Fractions which gave the desired mass were then analysed by analytical RP-HPLC to confirm purity, and those fractions which were pure were combined and lyophilised to give the reduced peptide. Oxidised peptides were purified by loading the acidified reaction mixtures onto a preparative

- 29 -

column at a flow rate of 8ml/min, washing through with 100%A until all oxidation buffer had eluted and then applying a 1% gradient (100%A to 80%B, 80min) with a flow rate of 8ml/min and u.v detection at 230nm. Fractions were collected and analysed as for the reduced peptides. If further purification was necessary the peptide was repurified on a semipreparative column on a 1% gradient (100%A to 80%B, 80min) with a flow rate of 3ml/min and u.v detection at 230nm. Fractions were collected and analysed as before.

Mass Spectrometry

10 Mass spectra were measured on a PE Sciex API-III triple quadrupole Ion Spray mass spectrometer. Data was obtained in the positive ion mode by the accumulation of data in the range 400-2100 amu from several scans using a scan step of 0.1 amu, and a delay time of 0.3 s.

Peptides were dissolved at a concentration of 1mg/ml in 45% aqueous acetonitrile containing 0.1% TFA. HPLC fractions were used without further treatment. Samples were delivered to the orifice via a glass capillary by direct injection (5-20ul) using a Rheodyne injector into a 30-40ul/min solvent flow of 50% aqueous acetonitrile containing 0.05% TFA. The resultant data was subjected to deconvolution (Hypermass - MacSpec 3.2, SCIEX, Canada) to determine the Mr of the observed protonated species.

20

Other high-resolution data were obtained on a Bruker Spectrospin BioAPEX external-ion-source Fourier transform electrospray mass spectrometer at a magnetic field of 4.7 T.

Data for some of the peptides synthesised is tabulated below

25

Table 3 List of synthesised peptides, optimal yields and Mass values.

PEPTIDE	REDUCED YIELD %	OXIDISED YIELD %	EXPECTED MASS (Mr,Da)	OBSERVED MASS (Mr,Da)
CVID	36	35	2755	2755
R ¹⁰ -CVID	36	40	2784	2784
D ⁹ R ¹⁰ -CVID	33	29	2812	2812

10 Example 3**Isolation and Characterisation of the CVID Gene Sequence****RNA extraction and cDNA synthesis**

15

Two specimens of *Conus catus* were collected from Lady Elliot Island on the Queensland Great Barrier Reef. The animals were anaesthetised on ice, and dissected to remove the venom duct in a region from the venom bulb to the proboscis. The ducts were sectioned, placed in a buffer containing guanidinium thiocyanate/N-lauroyl sarcosine, then emulsified

20 with manual grinding. Poly-A tailed mRNA was extracted from the mixtures using the Pharmacia Biotech QuickPrep mRNA purification system.

Strand-1 cDNA was 3' end synthesised from the *C. catus* poly-A mRNA templates using a NotI-d(T)₁₈ bifunctional primer (5'-AACTGGAAGAATTTCGCGGCCGCAGGAAT₍₁₈₎-3')
 25 (Pharmacia Biotech) in conjunction with Superscript II reverse transcriptase (Gibco BRL). The resultant cDNA templates were used to manufacture double stranded cDNA using a RNaseH/DNA polymerase procedure as per the Pharmacia Biotech cDNA Timesaver

- 31 -

protocol. Marathon (Clontech) adaptors were then added to the 5' and 3' ends of the ds-cDNA molecules to complete the cDNA construction. A representation of a complete coneshell venom peptide cDNA molecule is shown in figure 1.

5

PCR derivation of CVID and related cDNA sequences

PCR was carried out on samples containing ds-cDNA from *C. catus*, the CSRD-301A primer (5' - ATCATCAAAATGAAACTGACGTC - 3'), the ANCHOR primer (5' -
 10 AACTGGAAGAATTCGCGGCCGCAGGAAT - 3') and an appropriate *Tag* polymerase (Biotech International) and buffer (25mM Mg, 100uM deoxy-nucleotides, buffered at pH 8.5) in a thermal cycler (Omnigene) at 95°C/2 mins for 1 cycle, 95°C/30 sec - 55°C/60 sec - 72°C/90 sec for 35 cycles, and 72°C/10 mins for 1 cycle. This PCR produced a heterogeneous DNA product of approximately 380 bp to 500bp. Sequence analysis of clones
 15 derived from this PCR product have shown it to contain the sequence CVID as well as other related venom peptide sequences.

Cloning and sequencing of CVID

20 The DNA product produced from the CSRD-301A-ANCHOR driven PCR of *C. catus* cDNA was electrophoresed in low melting point agarose and excised. The DNA was extracted from the agarose on Qiagen columns, rephosphorylated with T4 DNA kinase (Progen), blunt ended with Klenow polymerase (Progen), and ligated with T4 DNA ligase (Progen) into the multiple cloning site of dephosphorylated *Sma-I* cut pUC-18 plasmid vector DNA
 25 (Pharmacia Biotech). The vector DNA was electrotransformed into Bluescript *E. coli* cells, to produce a library of clones representing the PCR product. Aliquots of the library were plated onto LB_{amp} plates, and individual clones selected and propagated overnight in TB_{amp} broth. Plasmid DNA was purified from the culture using the RPM system (BIO-101), and the PCR DNA inserts within the vector sequenced using the pUC-18 forward and reverse

- 32 -

primers (Pharmacia Biotech), di-deoxy terminator sequencing chemistries (Perkin Elmer) on ABI 373 sequencers. The sequence data was analysed using Sequence Navigator software (Applied Biosystems).

5 CVID gene sequence

Clone number Cca-6 within the *C. catus* CSRD-301A/ANCHOR venom duct cDNA PCR library provided the sequence for the CVID peptide. The nucleotide sequence and the anticipated translation of the associated amino acid sequence for the CVID gene are shown in figure 1. Further analysis of this clone library revealed a total of eight clones with identical sequence. All clones were sequenced in both orientations to produce a consensus sequence.

The CVID sequence has the following characteristics:

15

- A coding sequence of 222 base pairs which translate to 73 amino acids
- A predicted mature peptide sequence of 28 amino acids. It should be noted that in the protein isolated from snails the terminal glycine of the predicted expressed protein is removed by some form of post translational modification to leave an amidated C-terminal cystine.

25

- The predicted mature peptide has a six cysteine framework in the pattern of;
C-a₆-C-a₆-CC-a₃- C-a₆-C

The nucleotide and amino acid sequence of both the leader peptide and the mature peptide are not identical to any known peptide sequence.

Further experiments on *C. catus* similar to that described above were undertaken using some

additional primers in place of the CSRD-301A primer. These primers were designed to be more specific and were OM-2A (5'-ATC AAA ATG AAA CTG ACG TGT GTG GTG-3') and Cca-6-3B (5'-GCG TTT TGA TCA GCC ACA TCT ACC TA-3'). These experiments led to identification of sequences for some of the derivatives of CVID.

5

Example 4

Radioligand binding assays

Preparation of ^{125}I -GVIA and ^{125}I -MVIIC

10

Peptides were iodinated using IODO-GEN® (Fraker P.J. *et al.*, 1978) (1,3,4,6-tetrachloro-2a,6a-diphenyl-glycoluril) [Ahmad S.N. *et al.*, 1988, Cruz L.J. *et al.*, 1986], 5 μl (5.75 mg/ml, 17.4 mCi/mg) Na^{125}I (DuPont NEN®, New research products, Boston) and 25 μl of sodium phosphate buffer (50 mM, pH 7.4) were added to an eppendorf tube coated with IODO-GEN® (Pierce, Rockford, USA) and incubated for 5 mins. The reaction mixture was vortexed and transferred to an eppendorf tube containing 10 μl of the peptide of interest. This mixture was then allowed to react for another 5 min prior to purification by HPLC.

Preparative HPLC of ^{125}I -labelled peptides was performed on a Waters 680 gradient controller equipped with two Waters 510 HPLC pumps and a Waters 481 absorbance detector. Peptides were analysed on Vydac reverse phase C-18 analytical column (4.6 x 250 mm) eluted at 1 ml/min with a linear gradient of 0-67% of solvent B over 100 min: solvent A, 1% TFA (trifluoroacetic acid); solvent B, 90% ACN + 0.09% TFA. Separation was monitored at 214 nm and 1 ml fractions were collected. Fractions of interest were detected with a LKB Wallac 1272 automatic Gamma counter.

To confirm the identity of iodinated peptides, mass spectrometry was performed on a PE-SCIEX API III mass spectrometer (PE-Sciex, Thornhill, Ontario, Canada). HPLC fractions from peptides iodinated with non-radioactive K^{127}I were injected directly into the mass

- 34 -

spectrometer. Mass spectra were acquired on a Apple Macintosh IIfx computer using the software package MacSpec (Sciex, Toronto).

Rat Membrane Preparation

5

Rat membrane was prepared according to the procedure of Wagner *et al.* (1988). Rats were sacrificed by cervical dislocation and their brains removed and immediately frozen in liquid nitrogen. Frozen brains were stored at -78°C until required. Three brains (wet weight , 6.25 g) were thawed and homogenised with ultraturrex (IKA, 170 Watt) in 125 ml 50 mM HEPES pH 7.4. Homogenised brain was centrifuged at 16000rpm (35000g) for 20min at 4°C and the supernatant discarded. The pellet was resuspended by further homogenisation in 50mM HEPES, pH 7.4, 10 mM EDTA and incubated at 4°C for 30 min. Centrifugation was repeated as above and the supernatant discarded. The pellet was resuspended in 125ml 50mM HEPES, pH 7.4 (1:20 dilution) and stored at -78°C.

15

Binding Assays.

Binding experiments were performed as previously described (Kristipati *et al.*, 1994, Nadasdi *et al.*, 1995). Ligand binding assays were run in triplicate in glass tubes at room temperature. Briefly, assays were performed in 12 x 75 mm borasilicate culture tubes at room temperature and incubated for 1hr. Each tube contained 100µl each of test compound, iodinated ligand (7 fmol) and rat membrane (16 mg) added in this order. The assay buffer contained 20mM HEPES pH7.2, 75 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% BSA and protease inhibitors, 2 mM leupeptin and 0.5U aprotinin. The nonspecific binding was determined in the presence of either 17nM GVIA or 100 nM MVIIC. Assays were terminated by vacuum filtration on a Millipore manifold filtration system using glass fibre filters (Whatman GFB) presoaked in 0.6% polyethylenimine. Each tube was washed 3 times with 3ml ice-cold wash buffer (20mM HEPES pH7.2, 125mM NaCl and 0.1% BSA). Filters were counted on a gamma counter. In some instances, potency estimates at the N-type calcium channel were

- 35 -

determined by measuring ^{125}I -GVIA bound to rat brain membrane that was filtered using a Tomtec harvester and counted with a MicroBeta Jet scintillation counter. Similar results were obtained with both procedures. In all cases Graphpad Prism was used to generate binding curves and calculate EC_{50} values. Values for some of the compounds of the present invention are shown in Table 4.

Table 4: EC_{50} in rat brain binding assaysTable 4: EC_{50} in rat brain binding assays

PEPTIDE	^{125}I GVIA Assay	^{125}I MVIIC Assay
CVID □	3.1e^{-11} (2.3e^{-10})	7.1e^{-5} (6.4e^{-5})
R^{10} -CVID	7.5e^{-11} (5.3e^{-11})	$<3.5\text{e}^{-6}$ (1.2e^{-3})
D^9R^{10} -CVID	1.8e^{-9} (7.6e^{-10})	$<4.6\text{e}^{-5}$ ($<1.0\text{e}^{-3}$)
(4)	3.2e^{-11}	$<6.3\text{e}^{-7}$
(5)	2.15e^{-11}	$<7.1\text{e}^{-7}$
(7)	4.3e^{-11}	$<5.6\text{e}^{-7}$
(11)	4.57e^{-11}	$<4.3\text{e}^{-6}$
(12)	7.11e^{-11}	$<4\text{e}^{-6}$
(13)	5.03e^{-11}	$<4\text{e}^{-6}$
(14)	7.1e^{-10}	$<4.7\text{e}^{-6}$
(15)	4.4e^{-10}	$<4.6\text{e}^{-6}$
(18)	1.7e^{-10}	$<1.4\text{e}^{-6}$
(20)	3.5e^{-11}	$<3.4\text{e}^{-7}$
(21)	9.1e^{-11}	$<7.4\text{e}^{-7}$

Where two figures are quoted, the data in brackets represents data from initial binding studies while the other figure represents results obtained from further experiments.

Example 5

In view of the high level of selectivity shown by CVID for N-type VSCC, the structural features that might contribute to its N-type selectivity were investigated. This was done

using standard ^1H NMR techniques of the type known to those skilled in the art.

Methods

5 ^1H NMR structure studies

^1H NMR spectroscopy - All NMR experiments were recorded on a Bruker ARX 500 spectrometer equipped with a z-gradient unit or on a Bruker DMX 750 spectrometer equipped with a x,y,z-gradient unit. Peptide concentrations were in the range 1–5 mM. Each
10 analogue was examined in 95% H_2O /5% D_2O (pH 2.5–3.5). ^1H NMR experiments recorded were NOESY (Kumar et al., Jeener et al) with mixing times of 200 and 400 ms, and TOCSY (Bax) with a mixing time of 120 ms. All spectra were recorded at 293° K and were run over 6024 Hz (500 MHz) or 8192 Hz (750 MHz) with 4K data points, 400–512 FIDs, 16–64 scans, and a recycle delay of 1 s. Extra experiments recorded for CVID included NOESY
15 (100 ms mixing time), DQF-COSY (Rance), and E-COSY (Greisinger)(100% D_2O) at 293° K, and duplicate experiments at 280° K.

Solvent was suppressed using the WATERGATE sequence (Piotto et al., 1992) and spectra processed using UXNMR. FIDs were multiplied by a polynomial function and apodised using
20 a 90° shifted sine-bell function in both dimensions, or a mild Gaussian function in f_1 prior to Fourier transformation. Baseline correction using a 5th order polynomial was applied and chemical shift values were referenced internally to DSS at 0.00 ppm. Secondary $\text{H}\alpha$ shifts were measured using the random coil shift values of Marutka *et al.*, (1995).

25 $^3\text{J}_{\text{NH-H}\alpha}$ coupling constants were measured from high resolution 1D spectra (32 K) and compared to those obtained from the DQF-COSY spectra which were strip transformed to 8 K x 1 K and extracted using the Lorentzian line-fitting routine in the program Aurelia (Bruker GMBH). $^3\text{J}_{\text{H}\alpha\text{-H}\beta}$ coupling constants were measured directly from the E-COSY spectra transformed to high digital resolution (8 K x 1 K).

- 37 -

Distance restraints and structure calculations - Peak volumes in NOESY spectra were classified as strong, medium, weak, and very weak corresponding to upper bounds on interproton distances of 2.7, 3.5, 5.0, and 6.0 Å, respectively. Lower distance bounds were set to 1.8 Å. Appropriate pseudoatom corrections were made (Wüthrich *et al.*, 1983) and distances of 0.5 Å and 2.0 Å were added to the upper limits of restraints involving methyl and phenyl protons, respectively. $^3J_{\text{NH-H}\alpha}$ coupling constants were used to determine ϕ dihedral angle restraints [Pardi *et al.*, 1984] and $^3J_{\text{H}\alpha\text{-H}\beta}$ coupling constants, together with relevant NOESY peak strengths, were used to determine χ_1 dihedral angle restraints [Wagner *et al.*, 1987]. Where there was no diastereospecific assignment for a prochiral pair of protons, the largest upper bound for the two restraints was used but where stereospecific assignments were established, the distances were specified explicitly.

Structures were calculated using the torsion angle dynamics/ simulated annealing protocol in XPLOR version 3.8 [Brünger *et al.*, 1986; Brünger, 1992; Rice; Stein] using a geometric forcefield based on Engh and Huber parameters (Brooks *et al.*, 1983). Starting structures were generated *de novo* using random (ϕ , ψ) dihedral angles and energy minimised (500 steps) to produce structures with correct local geometry. The structures were subjected to a total of 15 ps of high temperature (50 000° K) molecular dynamics before cooling over 15 ps to 0° K and final energy minimisation (1000 steps). Structure refinements were performed using energy minimisation (1000 steps) under the influence of a modified Engh and Huber forcefield.

Data analysis - Structures were compared using pairwise and average RMSDs for the C α , C and N atoms (XPLOR version 3.8), and by calculating angular order parameters for the backbone dihedral angles [Hyberts *et al.*, 1992; Pallaghy *et al.*, 1993]. Structure visualisation was performed using INSIGHTII (MSI).

RESULTS

¹H NMR spectroscopy

5 The greatest difference in H α secondary shifts compared to MVIIA was seen in loops 2 and 4 of CVID. Differences in loop 4 are not surprising given that CVID has a novel sequence and incorporates two additional residues, the differences in loop 2 are noteworthy since loop 2 in MVIIA and CVID are similar. The secondary shifts of residues 9-14 in CVID follow the same basic pattern of those in MVIIA, but are of greater magnitude, indicating that the
10 structure of loop 2 in CVID may be more stabilised. This could stem from a long range interaction with loop 4. Loop 2 has previously been the least defined region of ω -conopeptide structure, with residues of this loop characterized by relatively broad peaks in the ¹H NMR spectra, indicative of conformational exchange (Nielsen *et al.*, 1996; Lew *et al.*, 1997). This lack of structure definition has hindered attempts to understand the crucial role
15 loop 2 plays in activity, function, and selectivity of ω -conopeptides, particularly that of the important binding determinant Tyr13, as well as residues of secondary importance such as Leu11 and Arg10 in MVIIA (Nadasdi *et al.*, 1995). Thus CVID may provide a novel structural template for pharmacophore development. Since the significant differences in secondary H α shifts for residues in loops 2 and 4 in CVID precluded accurate modelling of
20 CVID from existing ω -conotoxins structures, and given its enhanced N-type selectivity, the 3D structure of CVID was determined using ¹H NMR spectroscopy, as described below.

3D Structure of ω -conopeptide CVID

25 A set of 50 structures of CVID were calculated based a total of 481 distance restraints derived from 159 intraresidue, 110 sequential, 184 medium and long-range NOEs, 28 H-bond restraints defining a total of 14 H-bonds and 23 ϕ and 10 χ 1 dihedral angle restraints. A total of 47 structures converged to a consensus fold, with no NOE violation greater than 2 Å, and no dihedral violations greater than 3°. Of these, the 20 lowest energy structures were chosen

- 39 -

to represent the structure of CVID. The structures are exceptionally well defined, with a backbone pairwise RMSD of 0.35 Å (calculated over all residues). The angular order parameters (S) for the ϕ and ψ backbone dihedral angles averaged 0.99, indicating a high degree of structure precision that is reflected in the low the average RMSDs to the mean structure of 0.24 Å.

Novel features in CVID that have not been described for other ω -conotoxins include the presence of two hydrogen bonds between loops 2 and 4, from the NH protons of Lys10 and Leu11 to the C=O oxygen atoms of Gly22 and Thr23, respectively. It is possible that these hydrogen bonds enhance the stability of loop 2 in CVID compared with other ω -conotoxins. Importantly, the backbone of Tyr13 has been stabilized in a α_L conformation, with the χ_1 sidechain torsion angle at -60° . Attempts to define the conformation of Tyr13 in other ω -conotoxins have been ambiguous, and indeed Tyr13 may adopt an averaged conformation in other ω -conotoxins. The structural observations for the conformation of Tyr13 in CVID are supported by the presence of a strong intraresidue $NH_i-H\alpha_i$ NOE, together with a weaker $H\alpha_{i-1}-NH_i$ and a $^3J_{NH-H\alpha}$ coupling constant of 7 Hz.

Discussion

CVID was found to adopt a similar global fold to the known ω -conotoxins such as MVIIA, MVIIC and GVIA. This comparison also highlights significant differences in the structure of loop 4, which is oriented downwards in MVIIA (with the shortest loop 4) and MVIIC, outwards in GVIA, but curves towards loop 2 in CVID to create a more globular surface. The presence of two hydrogen bonds between loop 4 and loop 2 in CVID is likely to favour loop 4 in this orientation, and help stabilize loop 2. This is an interesting finding, as hydrogen bonds between loops 2 and 4 have not been reported previously for GVIA, MVIIA or MVIIC. This unique aspect of CVID structure may contribute to its improved selectivity for the N-type VSCC, and suggest that the loop 2/4 combination may contain important determinants for ω -conopeptide selectivity.

- 40 -

The high potency and selectivity of CVID make it an attractive candidate for pharmacophore development based on its 3D structure. The improved stability of loop 2 may contribute entropically to its superior selectivity over other ω -conotoxins found to date. However, 5 lacking the important secondary binding residues present in loop 4 of MVIIA (Arg21, Nadasdi *et al.*, 1995) and GVIA (Lys24, Tyr22; Lew *et al.*, 1997) it is likely that a unique set of ω -conotoxin/VSCC interactions originate from loop 4 in CVID, possibly through the relatively exposed Thr23 or Val24.

10 References

- Ahmad, S.N., *et al.*, (1988) *Brain Res.*, **453**, 247-56.
- Bax, A., and Davis, D.G., (1985) *J. Magn. Reson.*, **65**, 355-60.
- 15 Brooks, B., Brucoli, R., Olafson, B.O., States, D., Swaminathan, S., and Karplus, M. (1983) *J. Comput. Chem.* **4**, 187-217.
- Brünger, A.T., Clore, G.M., Gronenborn, A.M, and Karplus, M. (1986) *Proc. Nat. Acad. Sci.*, U.S.A. **83**, 3801-3805.
- 20 Brünger, A.T. (1992) X-PLOR version 3.1. A System for X-ray Crystallography and NMR. Yale University, New Haven, CT.
- 25 Cabot P.J., Cramond T.R., and Smith MT (1998), *Pul. Pharmacol. Ther.*, **10**(4), 215-221.
- Cleland *et al.*, *Crit Rev. Therap. Drug Carr, Syst.*, (1993), **10**, 307-366.
- Cruz, L. J., *et al.*, (1986) *J. Biol. Chem.*, **261**, 6230-6233.

- 41 -

Drugs of the Future, (1994), **19**(2), 128.

Drugs of the Future, (1998), **23**(2), 152.

5 Drug Data Report, (1993), **15**(9), 807.

Fraker, P.J. *et al.*, (1978) *Biochem. Biophys. Res. Commun* **80**, 849-857.

Greisinger, C., Sørensen, O.W., and Ernst, R.R. (1987). *J. Magn. Reson.* **75**, 474-492.

10

Heading C., (1999), *Curr. Opin. CPNS Investigational Drugs*, (1999), **1**(1), 153-166.

Hyberts, S.G., Goldberg, M.S., Havel, T.S., and Wagner, G. (1992) *Protein Sci.* **1**, 736-751.

15 Jeener, J., Meier, B.H., Bachmann, P., and Ernst, R.R. (1979) *J. Chem. Phys.* **71**, 4546-4553.

Kim, J. *et al.*, (1995) *Biochem. Biophys. Res. Commun.* **214**, 305-309.

Kristipati, R. *et al.*, *Molecular and Cellular Neurosciences*, **5**, 219-228 (1994).

20

Kumar, A., Ernst, R.R., and Wüthrich, K. (1980) *Biochem. Biophys. Res. Commun.* **95**, 1-6.

Lew, M. *et al.*, (1997) *J. Biol. Chem.*, **272**, 12014-12023.

25 M.Schnoltzer, *et al.*, *Int.J.Peptide Protein Res.* **40**, 180 (1992).

Nadasdi, L. *et al.*, (1995) *Biochemistry* **34**, 8076-8081.

Omote K. *et al.*, (1996) *Anesthesiology*, **84**, 636-43.

- Malmberg A. B., and Yaksh T. L., (1995) *J Neurosci.*, **14**, 4882-90.
- Marutka, G., Dyson, H.J., and Wright, P.E. (1995) *J. Biolmol. NMR* **5**, 14-24.
- 5 Nielsen, K.J., Skjærbæk, N., Dooley, M., Adams, D.A., Mortensen, M., Dodd., P., Craik, D.J., Alewood, P.F., and Lewis, R.J. (1999) *J. Med. Chem.* **42**, 415-426.
- Nielsen, K.J., Thomas, L., Lewis, R.J., Alewood, P.F., and Craik., D.J. (1996). *J. Mol. Biol.* **263**, 297-310.
- 10 Pallaghy, P.K., Duggan, B.M., Pennington, M.W., and Norton, R.S. (1993) *J. Mol. Biol.* **234**, 405-420.
- Pardi, A., Billeter, M., and Wüthrich, K. (1984) *J. Mol. Biol.* **180**, 741-751.
- 15 Piotto, M., Saudek, V., and Sklenár, V. (1992) *J. Biolmol. NMR* **2**, 661-665.
- Rance, M., Sorenson, O.W., Bodenhauser, G., Wagner, G., Ernst, R.R., and Wüthrich, K. (1983) *Biochem. Biophys. Res. Commun.* **177**, 479-485.
- 20 Ray, N.J., A.J. Jones and P. Keen, (1991), *Br. J. Pharmacol.* **102**, , 797-800.
- Rice, L.M., and Brunger, A.T. (1994) *Proteins: Struct. Funct. Genet.* **19**, 277-290.
- 25 Sarin V.K. *et al.*, *Anal.Biochem* **117**, 147 (1981).
- Sato, K. *et al.*, (1997) *FEBS Letters* **414**, 480-484.
- Stein, E.G., Rice, L.M., and Brunger, A.T. (1996) *J. Magn. Reson.* **124**, 1554-1564.

- 43 -

Wagner, G., Braun, W., Havel, T.F., Schaumann, T., Go, N., and Wüthrich, K. (1987) *J. Mol. Biol.* **196**, 611-639.

Wagner, J.A., *et al.*, (1988) *J. Neurosci.*, **8**, 3354-9.

5

White D. M. and Cousins M. J., *Brain Research*, (1998), **801**, 50-58.

Wüthrich, K., Billeter, M., and Braun, W. (1983) *J. Mol. Biol.* **169**, 949-961.

10

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

15

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in
20 this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

- 44 -

THE CLAIMS:

1. An isolated, synthetic or recombinant ω -conotoxin peptide in which the fourth loop
between cysteine residues 5 and 6 comprises the following sequence of amino
acids:

SGTVGR [SEQ ID NO: 1]

or such a sequence which has undergone one or more conservative amino acid
substitutions or side chain modifications.

2. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 1 in
which the fourth loop consists of the sequence:

SGTVGR [SEQ ID NO: 1]

or such a sequence which has undergone one or more amino acid substitutions or
side chain modifications.

3. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 1 or
claim 2 wherein each of the first, second and third loops of the ω -conotoxin peptide
corresponds to the loop of a naturally occurring ω -conotoxin peptide, or such a
sequence of amino acids which has undergone one or more amino acid
substitutions, additions or deletions.

4. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 1
wherein the second loop is selected from:

ART 34 AMDT

- 45 -

5 SKLMYD [SEQ ID NO: 2],
SRLMYD [SEQ ID NO: 3],
DRLMYD [SEQ ID NO: 4],
DKLMYD [SEQ ID NO: 33],
SKLAYD [SEQ ID NO: 34],
SKLNleYD [SEQ ID NO: 35],
SRLNleYD [SEQ ID NO: 36],
SKLOhmhserYD [SEQ ID NO: 37],
SKLOmserYD [SEQ ID NO: 38],

10

5. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 1 having the following sequence:

15 CKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 5]
CKSKGAKCSRLMYDCCSGSCSGTVGRC [SEQ ID NO: 6]
CKSKGAKCDRLMYDCCSGSCSGTVGRC [SEQ ID NO: 7]
CRSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 14]
CKSKGARCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 15]
CKSKGAQCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 16]
20 CKSKGAKCSKLMYDCCSGSCSGAVGRC [SEQ ID NO: 17]
CKSKGAKCDKLMYDCCSGSCSGTVGRC [SEQ ID NO: 18]
CKYKGAKCSRLMYDCCSGSCSGTVGRC [SEQ ID NO: 19]
CKSKGAKCSKLAYDCCSGSCSGTVGRC [SEQ ID NO: 20]
CKSKGAKCSKLMYDCCTGSCSGTVGRC [SEQ ID NO: 21]
25 CKSKDalAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 22]
CKSKGAKCSKLMYDCCSGSCSGTVGRCY [SEQ ID NO: 23]
CKSKGAKCSKLMYDCCSGSCSGTVGRC-OH [SEQ ID NO: 24]
YCKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 25]
Ac-CKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 26]

- 5 CKSKGAKCSKLNleYDCCSGSCSGTVGRC [SEQ ID NO: 27]
 CKSKGAKCSRLNleYDCCSGSCSGTVGRC [SEQ ID NO: 28]
 CKYKGAKCSRLNleYDCCSGSCSGTVGRC [SEQ ID NO: 29]
 CKSKGAKCSKLOmhserYDCCSGSCSGTVGRC [SEQ ID NO: 30]
 CKSKGAKCSKLOmserYDCCSGSCSGTVGRC [SEQ ID NO: 31]
 CKSKGAKCSKLM(O)YDCCSGSCSGTVGRC [SEQ ID NO: 32]

or such a sequence which has undergone one or more amino acid substitutions or side chain modifications.

- 10 6. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 5 having one of the following sequences:

- 15 CKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 5]
 CRSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 14]
 CKSKGARCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 15]
 CKSKGAKCSKLAYDCCSGSCSGTVGRC [SEQ ID NO: 20]
 CKSKGAKCSKLNleYDCCSGSCSGTVGRC [SEQ ID NO: 27]
 CKSKGAKCSRLNleYDCCSGSCSGTVGRC [SEQ ID NO: 28]
 20 CKSKGAKCSKLOmhserYDCCSGSCSGTVGRC [SEQ ID NO: 30]
 CKSKGAKCSKLOmserYDCCSGSCSGTVGRC [SEQ ID NO: 31].

- 25 7. An isolated, synthetic or recombinant ω -conotoxin peptide according to claim 1 having the following sequence:

CKSKGAKCSKLMYDCCSGSCSGTVGRC [SEQ ID NO: 5].

8. An isolated, synthetic or recombinant ω -conotoxin peptide according to any one of the preceding claims having a selectivity for N-type calcium channels over P/Q-

ART 34 AMDT

- 47 -

type calcium channels.

9. Use of an isolated, synthetic or recombinant ω -conotoxin peptide according to any one of the preceding claims in a receptor binding assay to test the calcium channel binding activity of a peptide or other compound.
10. An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a ω -conotoxin peptide according to any one of claims 1 to 8.
11. A nucleic acid probe comprising a sequence of nucleotides encoding or complementary to a sequence encoding all or part of an ω -conotoxin peptide according to any one of claims 1 to 8, said probe encoding or complementary to all or part of the fourth loop of said ω -conotoxin peptide.
12. A monoclonal or polyclonal antibody to an ω -conotoxin peptide according to any one of claims 1 to 8.
13. A genetic construct comprising a vector portion and a nucleic acid capable of encoding a peptide according to any one of claims 1 to 8.
14. A composition comprising: an isolated, synthetic or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

SGTVGR

[SEQ ID NO: 1]

or such a sequence which has undergone one or more conservative amino acid substitutions, and

ART 34 AMDT

- 48 -

a pharmaceutically acceptable carrier or diluent.

15. Use of an isolated, synthetic or recombinant ω -conotoxin peptide in which the
fourth loop between cysteine residues 5 and 6 comprises the following sequence of
5 amino acids:

SGTVGR

[SEQ ID NO: 1]

- 10 or such a sequence which has undergone one or more conservative amino acid
substitutions or side chain modifications in the manufacture of a medicament for
the treatment of a condition where blockade of N-type calcium channels is
associated with effective treatment.

16. Use of an isolated, synthetic or recombinant ω -conotoxin peptide in which the
15 fourth loop between cysteine residues 5 and 6 comprises the following sequence of
amino acids:

SGTVGR

[SEQ ID NO: 1]

- 20 or such a sequence which has undergone one or more conservative amino acid
substitutions or side chain modifications in the manufacture of a medicament for
the reduction of neuronal damage following ischemia, production of analgesia,
enhancement of opiate analgesia, treatment of schizophrenia or the treatment of
stimulant psychoses, hypertension, inflammation, diseases which cause
25 bronchoconstriction or for inhibition of progression of neuropathic pain.

17. A method for the treatment of conditions for which blockade of N-type calcium
channels is associated with effective treatment including the step of administering
to a mammal an effective amount of an isolated or recombinant ω -conotoxin

ART 34 AMDT

- 49 -

peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

SGTVGR

[SEQ ID NO: 1]

5

or such a sequence which has undergone one or more conservative amino acid substitutions or side chain modifications.

18. A method for reducing neuronal damage following ischemia, for the production of analgesia, for enhancement of opiate analgesia, for the treatment of schizophrenia, hypertension, inflammation or diseases which cause bronchoconstriction, stimulant psychoses or for inhibition of progression of neuropathic pain including the step of administering to a mammal an effective amount of an isolated or recombinant ω -conotoxin peptide in which the fourth loop between cysteine residues 5 and 6 comprises the following sequence of amino acids:

SGTVGR

[SEQ ID NO: 1]

20

or such a sequence which has undergone one or more conservative amino acid substitutions or side chain modifications.

19. Use of an isolated, synthetic or recombinant ω -conotoxin peptide according to any one of the preceding claims in a screen to identify compounds with activity at N-type VSCCs.

25

WO 99/54350

- 1 -

SEQUENCE LISTING

5

<110> THE UNIVERSITY OF QUEENSLAND

10

15 <120> NOVEL PEPTIDES

20 <130> MJC/RR

25 <140>

30 <141>

35 <150> PP2989

<151> 1998-04-16
40

45 <150> PP8419

<151> 1999-02-01

50

<160> 29
55

60 <170> PatentIn Ver. 2.0

65 <210> 1

- 2 -

<211> 6

5

<212> PRT

<213> Conus catus

10

15 <400> 1

Ser Gly Thr Val Gly Arg

20

1

5

25

30 <210> 2

<211> 6

35

<212> PRT

<213> Conus magus

40

45 <400> 2

Ser Lys Leu Met Tyr Asp

50

1

5

55

60 <210> 3

<211> 6

65

- 3 -

<212> PRT

5 <213> Conus catus

10 <220>

15 <223> Description of Artificial Sequence:synthetic

<400> 3

20 Ser Arg Leu Met Tyr Asp

25 1 5

30

<210> 4

35 <211> 6

40 <212> PRT

<213> Artificial Sequence

45

<220>

50 <223> Description of Artificial Sequence:synthetic

55 <400> 4

60 Asp Arg Leu Met Tyr Asp

1 5

65

項目	単位	数値
1. 総人口	人	1,234,567
2. 男性人口	人	612,345
3. 女性人口	人	622,222
4. 総世帯数	世帯	234,567
5. 男性世帯数	世帯	112,345
6. 女性世帯数	世帯	122,222
7. 総労働人口	人	876,543
8. 男性労働人口	人	438,271
9. 女性労働人口	人	438,272
10. 総消費支出	円	123,456,789
11. 男性消費支出	円	61,728,394
12. 女性消費支出	円	61,728,395
13. 総貯蓄額	円	98,765,432
14. 男性貯蓄額	円	49,382,716
15. 女性貯蓄額	円	49,382,716
16. 総所得	円	156,789,012
17. 男性所得	円	78,394,506
18. 女性所得	円	78,394,506
19. 総資産	円	234,567,890
20. 男性資産	円	117,283,945
21. 女性資産	円	117,283,945
22. 総負債	円	123,456,789
23. 男性負債	円	61,728,394
24. 女性負債	円	61,728,395
25. 総純資産	円	111,111,111
26. 男性純資産	円	55,555,555
27. 女性純資産	円	55,555,556
28. 総人口密度	人/平方キロメートル	123.45
29. 男性人口密度	人/平方キロメートル	61.72
30. 女性人口密度	人/平方キロメートル	61.73
31. 総労働人口密度	人/平方キロメートル	87.65
32. 男性労働人口密度	人/平方キロメートル	43.82
33. 女性労働人口密度	人/平方キロメートル	43.83
34. 総消費支出密度	円/平方キロメートル	12,345,678
35. 男性消費支出密度	円/平方キロメートル	6,172,839
36. 女性消費支出密度	円/平方キロメートル	6,172,839
37. 総貯蓄額密度	円/平方キロメートル	9,876,543
38. 男性貯蓄額密度	円/平方キロメートル	4,938,271
39. 女性貯蓄額密度	円/平方キロメートル	4,938,272
40. 総所得密度	円/平方キロメートル	15,678,901
41. 男性所得密度	円/平方キロメートル	7,839,450
42. 女性所得密度	円/平方キロメートル	7,839,450
43. 総資産密度	円/平方キロメートル	23,456,789
44. 男性資産密度	円/平方キロメートル	11,728,394
45. 女性資産密度	円/平方キロメートル	11,728,395
46. 総負債密度	円/平方キロメートル	12,345,678
47. 男性負債密度	円/平方キロメートル	6,172,839
48. 女性負債密度	円/平方キロメートル	6,172,839
49. 総純資産密度	円/平方キロメートル	11,111,111
50. 男性純資産密度	円/平方キロメートル	5,555,555
51. 女性純資産密度	円/平方キロメートル	5,555,556
52. 総人口増加率	%	1.23
53. 男性人口増加率	%	0.61
54. 女性人口増加率	%	0.62
55. 総世帯数増加率	%	0.23
56. 男性世帯数増加率	%	0.11
57. 女性世帯数増加率	%	0.22
58. 総労働人口増加率	%	0.87
59. 男性労働人口増加率	%	0.43
60. 女性労働人口増加率	%	0.88
61. 総消費支出増加率	%	12.34
62. 男性消費支出増加率	%	6.17
63. 女性消費支出増加率	%	12.35
64. 総貯蓄額増加率	%	9.87
65. 男性貯蓄額増加率	%	4.93
66. 女性貯蓄額増加率	%	9.88
67. 総所得増加率	%	15.67
68. 男性所得増加率	%	7.83
69. 女性所得増加率	%	15.68
70. 総資産増加率	%	23.45
71. 男性資産増加率	%	11.72
72. 女性資産増加率	%	23.46
73. 総負債増加率	%	12.34
74. 男性負債増加率	%	6.17
75. 女性負債増加率	%	12.35
76. 総純資産増加率	%	11.11
77. 男性純資産増加率	%	5.55
78. 女性純資産増加率	%	11.12
79. 総人口密度増加率	%	1.23
80. 男性人口密度増加率	%	0.61
81. 女性人口密度増加率	%	0.62
82. 総労働人口密度増加率	%	0.87
83. 男性労働人口密度増加率	%	0.43
84. 女性労働人口密度増加率	%	0.88
85. 総消費支出密度増加率	%	12.34
86. 男性消費支出密度増加率	%	6.17
87. 女性消費支出密度増加率	%	12.35
88. 総貯蓄額密度増加率	%	9.87
89. 男性貯蓄額密度増加率	%	4.93
90. 女性貯蓄額密度増加率	%	9.88
91. 総所得密度増加率	%	15.67
92. 男性所得密度増加率	%	7.83
93. 女性所得密度増加率	%	15.68
94. 総資産密度増加率	%	23.45
95. 男性資産密度増加率	%	11.72
96. 女性資産密度増加率	%	23.46
97. 総負債密度増加率	%	12.34
98. 男性負債密度増加率	%	6.17
99. 女性負債密度増加率	%	12.35
100. 総純資産密度増加率	%	11.11
101. 男性純資産密度増加率	%	5.55
102. 女性純資産密度増加率	%	11.12

```

5      <210> 5
      <211> 27
10     <212> PRT
      <213> Conus catus
20
      <400> 5
25     Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys
      1              5              10              15
30
      Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
35              20              25
40
45     <210> 6
      <211> 27
50     <212> PRT
      <213> Artificial Sequence
55
60     <220>
      <223> Description of Artificial Sequence:synthetic
65

```

- 5 -

<400> 6

5

Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys

10 1 5 10 15

15 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

20 20 25

25

<210> 7

30 <211> 27

<212> PRT

35

<213> Artificial Sequence

40

<220>

45 <223> Description of Artificial Sequence:synthetic

50 <400> 7

Cys Lys Ser Lys Gly Ala Lys Cys Asp Arg Leu Met Tyr Asp Cys Cys

55 1 5 10 15

60

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

65 20 25

- 6 -

PCT/99/06296

5

10 <210> 8

<211> 25

15 <212> PRT

<213> Conus magus

20

25 <400> 8

Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys

30 1 5 10 15

35 Thr Gly Ser Cys Arg Ser Gly Lys Cys

40 20 25

45

<210> 9

50 <211> 26

55 <212> PRT

<213> Conus magus

60

<400> 9

65

- 7 -

Cys Lys Gly Lys Gly Ala Pro Cys Arg Lys Thr Met Tyr Asp Cys Cys

5 1 5 10 15

10 Ser Gly Ser Cys Gly Arg Arg Gly Lys Cys

15 20 25

20
<210> 10

25 <211> 33

<212> PRT

30
<213> Conus geographus35
<400> 1040
Cys Lys Ser Hyp Gly Ser Ser Cys Ser Hyp Thr Ser Tyr Asn Cys Cys Arg

45 1 5 10 15

50 Ser Cys Asn Hyp Tyr Thr Lys Arg Cys Tyr
20 25

55

60

65 <210> 11

[illegible]

18

- 9 -

<400> 12

5 atcatcaaa atg aaa ctg acg tgt gtg gtg atc gtc gcc gtg ctg ctc ctg 51

Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu

10 1 5 10

15 acg gcc tgt caa ctc atc aca gct aat gac tcc aga ggt acg cag aag 99

Thr Ala Cys Gln Leu Ile Thr Ala Asn Asp Ser Arg Gly Thr Gln Lys

15 20 25 30

25

cat cgt gcc ctg agg tgg gac acc aaa ctc tcc atg tgg act cgc tgc 147

30 His Arg Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys

35 35 40 45

40 aag agt aaa gga gca aaa tgt tca aag ctt atg tat gac tgc tgc agc 195

Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys Ser

45 50 55 60

50
ggt tct tgc agc ggc acc gta ggt aga tgt ggc tgatccggcg cttgatctcc 248

55 Gly Ser Cys Ser Gly Thr Val Gly Arg Cys Gly

65 70

60

65 cccttctgtg ctctatcctt ttctgctga gtctctctta cctgagagtg gtcatgaacc 308

- 10 -

5 actcatcacc taccctctgg aggtctcaaa gaactacttg aaataaagcc gcttgcaaaa 368

10 aaaaaaaaaa aaaa 382

15

20 <210> 13

<211> 73

25 <212> PRT

<213> Conus catus

30

35 <400> 13

Met Lys Leu Thr Cys Val Val Ile Val Ala Val Leu Leu Leu Thr Ala

40 1 5 10 15

45 Cys Gln Leu Ile Thr Ala Asn Asp Ser Arg Gly Thr Gln Lys His Arg

50 20 25 30

55 Ala Leu Arg Ser Asp Thr Lys Leu Ser Met Ser Thr Arg Cys Lys Ser

60 35 40 45

65 Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys Ser Gly Ser

- 11 -

007727-0042980

50 55 60

5
Cys Ser Gly Thr Val Gly Arg Cys Gly

10 65 70

15
<400> 14

20
Cys Arg Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

25 1 5 10 15

30 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

20 25

35

40
<210> 12

45 <211> 27

<212> PRT

50
<213> Conus catus

55
<400> 15

60 Cys Lys Ser Lys Gly Ala Arg Cys Ser Lys Leu Met Tyr Asp Cys Cys

1 5 10 15

65

- 12 -

Pub. No. 99/00288

5 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
20 25

10

15 <210> 13
<211> 27
20 <212> PRT
25 <213> Conus catus

30 <400> 16

35 Cys Lys Ser Lys Gly Ala Gln Cys Ser Lys Leu Met Tyr Asp Cys Cys
1 5 10 15

40

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
45 20 25

50

55 <210> 14
<211> 27
60 <212> PRT
65 <213> Artificial Sequence

- 13 -

5 <220>

<223> Description of Artificial Sequence:synthetic

10

<400> 17

15 Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

1

5

10

15

20

25 Ser Gly Ser Cys Ser Gly Ala Val Gly Arg Cys

20

25

30

35

<210> 15

40 <211> 27

<212> PRT

45 <213> Artificial Sequence

50

<220>

55 <223> Description of Artificial Sequence:synthetic

60 <400> 18

Cys Lys Ser Lys Gly Ala Lys Cys Asp Lys Leu Met Tyr Asp Cys Cys

65

1

5

10

15

- 14 -

5 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

10 20 25

15

<210> 16

20 <211> 27

25 <212> PRT

<213> Artificial Sequence

30

<220>

35 <223> Description of Artificial Sequence:synthetic

40 <400> 19

45 Cys Lys Tyr Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys

1 5 10 15

50

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

55 20 25

60

65 <210> 17

- 15 -

Pub. No. 99/00288

<211> 27
5
<212> PRT
10 <213> Artificial Sequence
15 <220>
<223> Description of Artificial Sequence:synthetic
20
<400> 20
25 Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Ala Tyr Asp Cys Cys
30 1 5 10 15
35 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
20 25
40
45
<210> 18
50 <211> 27
<212> PRT
55 <213> Artificial Sequence
60
<220>
65 <223> Description of Artificial Sequence:synthetic

- 16 -

5 <400> 21

Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

10 1 5 10 15

15 Thr Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

20 20 25

25

<210> 19

30 <211> 27

35 <212> PRT

<213> Artificial Sequence

40

<220>

45 <223> Description of Artificial Sequence:synthetic

50 <400> 22

55 Cys Lys Ser Lys Xaa Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

1 5 10 15

60

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

65

Pub No. 1999/00288

- 17 -

20

25

5

10 <210> 20

<211> 28

15

<212> PRT

20 <213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:synthetic

30

<400> 23

35

Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

40

1

5

10

15

45 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys Tyr

20

25

50

55

<210> 21

60 <211> 27

<212> PRT

65

PCT/99/064286

- 18 -

<213> Artificial Sequence

5

<220>

10 <223> Description of Artificial Sequence:synthetic

15 <400> 24

Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys Cys

20

1

5

10

15

25

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

30

20

25

35

40 <210> 22

<211> 28

45 <212> PRT

<213> Artificial Sequence

50

55 <220>

<223> Description of Artificial Sequence:synthetic

60

<400> 25

65 Tyr Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp Cys

[illegible]

```

1
5
10
15
5
10 Cys Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
20
25
15
20
25 <210> 23
<211> 29
<212> PRT
30 <213> Artificial Sequence
35
<220>
40 <223> Description of Artificial Sequence:synthetic
45
<400> 26
Cys Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Met Tyr Asp
50 1 5 10 15
55
Cys Cys Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
60
65

```


- 20 -

Sequence of the protein

5 <210> 24
 <211> 27
10 <212> PRT
 <213> Artificial Sequence
15
 <220>
20 <223> Description of Artificial Sequence:synthetic
25
 <400> 27
30 Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Xaa Tyr Asp Cys Cys
 1 5 10 15
35
 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys
40 20 25
45
50 <210> 25
 <211> 27
55 <212> PRT
60 <213> Artificial Sequence
65 <220>

- 21 -

<223> Description of Artificial Sequence:synthetic

5

<400> 28

10

Cys Lys Ser Lys Gly Ala Lys Cys Ser Arg Leu Xaa Tyr Asp Cys Cys

15 1 5 10 15

20 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

25 20 25

30

<210> 26

35 <211> 27

<212> PRT

40

<213> Artificial Sequence

45

<220>

50 <223> Description of Artificial Sequence:synthetic

55 <400> 29

Cys Lys Tyr Lys Gly Ala Lys Cys Ser Arg Leu Xaa Tyr Asp Cys Cys

60 1 5 10 15

65

- 22 -

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

5 20 25

10

<210> 27

15 <211> 27

20 <212> PRT

<213> Artificial Sequence

25

<220>

30 <223> Description of Artificial Sequence:synthetic

35 <400> 30

40 Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Xaa Tyr Asp Cys Cys

1 5 10 15

45

Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

50 20 25

55

60 <210> 28

<211> 27

65

- 23 -

<212> PRT

5 <213> Artificial Sequence

10 <220>

<223> Description of Artificial Sequence:synthetic

15

<400> 31

20 Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Xaa Tyr Asp Cys Cys

25 1 5 10 15

30 Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

35 20 25

40

<210> 32

45 <211> 28

<212> PRT

50 <213> Artificial Sequence

55

<220>

60 <223> Description of Artificial Sequence:synthetic

65 <400> 32

- 24 -

Cys Lys Ser Lys Gly Ala Lys Cys Ser Lys Leu Xaa Tyr Asp Cys

5 1 5 10 15

Cys Ser Gly Ser Cys Ser Gly Thr Val Gly Arg Cys

10 20 25

15 <210> 33

<211> 6

20 <212> PRT

25 <213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence: Synthetic
35

40 <400> 33

Asp Lys Leu Met Tyr Asp

45 1 5

50

55 <210> 34

<211> 6

60 <212> PRT

<213> Artificial Sequence
65

- 25 -

5 <220>

<223> Description of Artificial Sequence:Synthetic

10

<400> 34

15

Ser Lys Leu Ala Tyr Asp

20

1

5

25

<210> 35

30

<211> 6

35

<212> PRT

<213> Artificial Sequence

40

<220>

45

<223> Description of Artificial Sequence:Synthetic

50

<400> 35

55 Ser Lys Leu Xaa Tyr Asp

1

5

60

65

- 26 -

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

<210> 36

5 <211> 6

<212> PRT

10 <213> Artificial Sequence

15 <220>

20 <223> Description of Artificial Sequence:Synthetic

25 <400> 36

Ser Arg Leu Xaa Tyr Asp

30 1 5

35

40 <210> 37

<211> 6

45 <212> PRT

50 <213> Artificial Sequence

55 <220>

60 <223> Description of Artificial Sequence:Synthetic

65 <400> 37

```

5      1      5

10

    <210> 38

15    <211> 6

    <212> PRT

20    <213> Artificial Sequence

25

    <220>

30    <223> Description of Artificial Sequence:Synthetic

35

    <400> 38

40 Ser Lys Leu Xaa Tyr Asp

      1      5

45

50

```


FIGURE 1

atcatcaaa

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
ATG	AAA	CTG	ACG	TGT	GTG	GTG	ATC	GTC	GCC	GTG	CTG	CTC	CTG	ACG
M	K	L	T	C	V	V	I	V	A	V	L	L	L	T
16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
GCC	TGT	CAA	CTC	ATC	ACA	GCT	AAT	GAC	TCC	AGA	GGT	ACG	CAG	AAG
A	C	Q	L	I	T	A	N	D	S	R	G	T	Q	K
31	32	33	34	35	36	37	38	39	40	41	42	43	44	45
CAT	CGT	GCC	CTG	AGG	TCG	GAC	ACC	AAA	CTC	TCC	ATG	TCG	ACT	CGC
H	R	A	L	R	S	D	T	K	L	S	M	S	T	R
46	47	48	49	50	51	52	53	54	55	56	57	58	59	60
TGC	AAG	AGT	AAA	GGA	GCA	AAA	TGT	TCA	AAG	CIT	ATG	TAT	GAC	TGC
C	K	S	K	G	A	K	C	S	K	L	M	Y	D	C

61 62 63 64 65 66 67 68 69 70 71 72 73 74
TGC AGC GGT TCT TGC AGC GGC ACC GTA GGT AGA TGT GGC TGA tcc
C S G S C S S G T V G R C G
ggcgcttgatcccccttctgtgctctatctcttcttgcgagtcctcttaccctgagagtggtcatgaaccactcatcacctacccccctggaggt
ctcaagaactacttgaaataaagccgcttgcaaaaaaaaaaaaaaaaa

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY <small>(Includes Reference to PCT International Application)</small>	Docket # 13922
--	---------------------------------

As a below named inventor, I hereby declare that
My residence, post office address and citizenship are as stated below next to my name.
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

NOVEL OMEGA CONOTOXIN PEPTIDES

the specification of which (check only one item below):

- ☐ is attached hereto
- ☐ was filed as United States application

Serial No. _____
on _____
and was amended
on _____ (if applicable)

- ☒ was filed as PCT international application

Number PCT/AU99/00288
on 16 April 1999
and was amended under PCT Article 19
on _____ (if applicable).

and was amended under Article 34 on 17 February, 2000.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:			
COUNTRY <small>(PCT and date, PCT)</small>	APPLICATION NUMBER	DATE OF FILING <small>(day month year)</small>	PRIORITY CLAIMED <small>UNDER 35 USC 119</small>
Australia	PP2989/98	16 April 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Australia	PP8419/99	1 February 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO



In the Reference to PCT file 310, 3 APR 1975

[illegible]

100
200
300

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Stephen D. Murphy, Reg. No. 22,002; Leopold Presser, Reg. No. 19,827; William C. Roch, Reg. No. 24,972; Kenneth L. King, Reg. No. 24,223; Frank S. DiGiglio, Reg. No. 31,346; Paul J. Esatto, Jr., Reg. No. 30,749; John S. Sensny, Reg. No. 28,757; Mark J. Cohen, Reg. No. 32,211; Richard L. Catania, Reg. No. 32,608 and Donald T. Black, Reg. No. 27,999.

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530

Direct Telephone Calls to
(name and telephone number)
Leopold Presser
(516) 742-4343

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon

SIGNATURE OF INVENTOR 203

DATE _____

27/10/00

Page 2 of 2

400

204	FULL NAME OF INVENTOR	FAMILY NAME <u>NIELSEN</u>	FIRST GIVEN NAME <u>Katherine</u>	SECOND GIVEN NAME <u>Justine</u>
	RESIDENCE & CITIZENSHIP	<u>Chapel Hill</u>	STATE OR FOREIGN COUNTRY <u>Queensland</u> <i>Aux</i>	COUNTRY OF CITIZENSHIP <u>Australia</u>
	POST OFFICE ADDRESS	<u>17 Lambourn Street</u>	CITY <u>Chapel Hill</u>	STATE & ZIP CODE COUNTRY <u>Queensland 4069, Australia</u>
205	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
206	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
207	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
208	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
209	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon

SIGNATURE OF INVENTOR 204 X <i>Kath Nielsen</i>	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE X <i>27/10/00</i>	DATE	DATE
SIGNATURE OF INVENTOR 207	SIGNATURE OF INVENTOR 208	SIGNATURE OF INVENTOR 209
DATE	DATE	DATE